Brought to you by 
Forma and Novartis enter potential $200mm deal
Jan 2009
Executive Summary
In a deal that gives Novartis AG options to cancer therapeutics, the Big Pharma's Novartis Option Fund has entered into an agreement with biotech start-up Forma Therapeutics for the discovery of new drug targets.
Deal Industry
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
-
Molecular Diversity
- Natural Products
-
Drug Discovery Tools
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R+D and Marketing-Licensing
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Forma and Novartis enter potential $200mm deal
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice